RT Conference Proceedings
T1 RELAY EU/US Subset: Ramucirumab Plus Erlotinib Improves Progression-Free Survival in First-Line EGFR Mutation-Positive NSCLC
A1 Aix, S.
A1 Novello, S.
A1 Garon, E.
A1 Nakagawa, K.
A1 Nadal, E.
A1 Moro-Sibilot, D.
A1 Alonso Garcia, M.
A1 Fabre, E.
A1 Frimodt-Moller, B.
A1 Zimmermann, A.
A1 Visseren-Grul, C.
A1 Reck, M.
K1 EU/US subset
K1 EGFR-mutation positive NSCLC
K1 Ramucirumab
PB Elsevier science inc
SN 1556-0864
YR 2019
FD 2019-10-01
LK https://hdl.handle.net/10668/27251
UL https://hdl.handle.net/10668/27251
LA en
DS RISalud
RD Apr 10, 2025